Mitotically Active Leiomyoma of the Uterus in a Postmenopausal Breast Cancer Patient Receiving Tamoxifen

I-Feng Liu, Yu-Shan Yen, Ya-Min Cheng, Cheng-Yang Chou
Taiwanese journal of obstetrics & gynecology · 2006 · vol. 45(2) , pp. 167–169 · doi:10.1016/s1028-4559(09)60218-7 · PMID:17197361 · W1966534674
article OA: diamond CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This case report describes a postmenopausal breast cancer patient on tamoxifen who developed mitotically active leiomyoma of the uterus, adenomyosis, and endometrial proliferation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: Mitotically active leiomyoma of the uterus complicated with postmenopausal vaginal bleeding has never been reported in Taiwan. Here, we present a case of mitotically active leiomyoma of the uterus complicated with postmenopausal vaginal bleeding in a breast cancer patient who had been receiving tamoxifen for 2 years. CASE REPORT: A 56-year-old woman visited our clinic due to abnormal vaginal spotting for 3 months. This patient had been menopausal for about 6 years without hormone replacement therapy. She had been suffering from breast cancer, had undergone conservative breast surgery, and had been taking tamoxifen (20 mg/day) for 2 years. Pelvic ultrasound was performed and revealed an 8.9 x 7.7 cm uterine mass. After simple total hysterectomy, we found an enlarged uterus with a mass over the posterior wall. Final pathology demonstrated a mitotically active leiomyoma, adenomyosis of the uterus, and proliferation of the endometrium. CONCLUSION: Endometrial cancer is rarely noted in breast cancer patients taking tamoxifen. Further, none have reported mitotically active leiomyoma of the uterus. From this case, endometrial proliferation and mitotically active leiomyoma of the uterus may be related to tamoxifen therapy, and should not be neglected in breast cancer patients.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Antineoplastic Agents, Hormonal Breast Neoplasms Leiomyoma Mitosis Postmenopause Tamoxifen Uterine Neoplasms Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Breast Neoplasms Endometriosis Endometriosis Endometriosis Endometrium Endometrium Female Humans Hysterectomy Leiomyoma Leiomyoma

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

Cited by (1)

References (14)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-12T06:13:51.797165+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:15:06.633332+00:00
License: CC0 · commercial use OK